ID | 1166 |
Name of the vaccine | Pentaxim |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | From 2 months |
Description of the vaccine | Adsorbed diphtheria, tetanus, pertussis (acellular component), inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine. |
Name of the manufacturer | Sanofi Pasteur Ltd |
Name of the manufacturing country | Thailand |
Year of manufacture | 1997 |
Clinical Phase status | Approved |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | 92.2–100% of infants achieved seroprotective levels of anti-PRP (greater than or equal to 0.15 µg/ml) antibodies. |
Vaccine formulation | Powder and suspension |
Dosage | Two injections at 2 and 4 months of age and a booster at the age of 11 months OR three injections, gap of 1 to 2 months and booster within the second year of life. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Immunization against diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Hib. |
Export | Marketing Authorisation Holder: Sanofi Pasteur SA, France |
Approval | European Union Pharmacopoeia |
Adjuvant | Aluminium hydroxide |
Repurposing | For diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Hib. |
Side effects of vaccine | Injection site redness, swelling, pain, fever, vomiting, irritability, abnormal crying, nervousness, loss of appetite, somnolence. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 21749196 |
Clinical trial number | NA |
Reference | https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR2C1062470002211C-SPC.pdf |
Other name | NA |
Additional Links | NA
|